Nucleoside News and Research

RSS

BARACLUDE data show low resistance over 5 years in nucleoside-naive hepatitis B patients

New BARACLUDE (entecavir) data presented demonstrated a continued low incidence of resistance in nucleoside-naïve patients through five years of treatment. In the nucleoside-naïve chronic hepatitis B patients analyzed, no additional patient developed resistance in the fifth year (n=108).

25 Mar 2008

HIV drugs, Abacavir and Didanosine increase the risk of heart attack

A study to assess the adverse effects of anti-retroviral drugs shows that two widely-used HIV drugs are associated with an increased risk of heart attack/the formation of blood clots in the heart.

8 Feb 2008

New anti-HIV medication etravirine shows great promise

The AIDS Institute, a national public policy research, advocacy, and education organization, is encouraged with the FDA's approval of the first new non-nucleoside reverse transcriptase inhibitor (NNRTI) in nearly a decade.

4 Feb 2008

AIDS Healthcare Foundation criticizes Etravirine's pricing

AIDS Healthcare Foundation (AHF) has urged Tibotec Pharmaceuticals Ltd., a division of Johnson & Johnson, to reconsider and reduce its steep price for its newest AIDS drug, etravirine (TMC 125), a non-nucleoside reverse transcriptase inhibitor, (NNRTI), which received Food and Drug Administration (FDA) approval on Friday after a fast track or 'priority review' and approval process granted to companies for medications and therapies intended to treat life-threatening illnesses such as AIDS.

22 Jan 2008

FDA approves etravirine tablets for HIV

The U.S. Food and Drug Administration has approved etravirine tablets for the treatment of HIV infection in adults who have failed treatment with other antiretrovirals.

21 Jan 2008

New HIV drug will help millions

Statistics released by the World Health Organisation (WHO) indicate that as many as 33 million people worldwide are currently living with the HIV virus which also killed 2 million people in 2007.

20 Jan 2008

HIV drug resistance risk in mothers reduced by tenofovir/emtricitabine with nevirapine during labor

New research from the University of Alabama at Birmingham (UAB) shows that adding a single dose of two common anti-HIV drugs can prevent HIV-positive pregnant women from developing resistance to an entire class of drugs, potentially improving future treatment options.

14 Nov 2007

Ardea Biosciences completes phase 1 trials of HIV drug RDEA806

Ardea Biosciences, Inc. has announced that it has successfully completed Phase 1 single-ascending-dose, multiple-ascending-dose, food-effect, and drug-interaction studies of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor (NNRTI), in healthy volunteers.

5 Sep 2007

Tibotec Pharmaceuticals submits NDA for investigational HIV treatment

Tibotec Pharmaceuticals Ltd. has announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) for TMC125 (etravirine), an investigational non- nucleoside reverse transcriptase inhibitor (NNRTI), being studied for use with other antiretroviral (ARV) agents as a treatment for people infected with HIV- 1.

19 Jul 2007

Etravirine reduces HIV viral loads when taken with Prezista

The experimental antiretroviral drug etravirine, made by Johnson & Johnson subsidiary Tibotec Pharmaceuticals, greatly reduces HIV viral loads in people with a history of drug resistance when taken in combination with Tibotec's antiretroviral Prezista, according to two studies published Saturday in the journal The Lancet.

10 Jul 2007

Etravirine effective for HIV supression

Treatment with TMC125 (etravirine) leads to better virological suppression than placebo as part of antiretroviral therapy in patients with documented resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs), conclude two randomised trials in this week's issue of The Lancet.

8 Jul 2007

FDA fast tracks ViroPharma's treatment of hepatitis C

ViroPharma has announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for HCV-796 for treatment of hepatitis C virus infection.

28 Jun 2007

Entecavir can compromise HIV treatment

Treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal, according to a new report in the New England Journal of Medicine.

23 Jun 2007

Major breakthrough for people with AIDS is on the horizon

Three new drugs are predicted to help transform the long-term prognosis for people with the AIDS virus, says an editorial in the journal, which points towards highly promising results from trials of three new drugs.

1 Jun 2007

Drg resistant HIV quickly hides in infants' cells

New evidence shows that drug-resistant virus passed from mother-to-child can quickly establish itself in infants, CD4+ T cells where it can hide for years, likely limiting their options for future treatment.

1 May 2007

Bristol-Myers Squibb announces new results of Baraclude (entecavir) resistance monitoring program

Bristol-Myers Squibb Company has announced new results of the Baraclude (entecavir) resistance monitoring program, which found a continued low incidence of resistance in studies of nucleoside-naive chronic hepatitis B patients through four years of treatment.

16 Apr 2007

Two experimental drugs aimed at controlling viral loads among HIV-positive people who have developed drug resistance show promise

Two experimental antiretroviral drugs, called TMC278 and elvitegravir, show promise in controlling the viral loads of HIV-positive people who have developed resistance to available drugs, researchers said Wednesday at the 14th Annual Conference on Retroviruses and Opportunistic Infections in Los Angeles, the Los Angeles Times reports.

4 Mar 2007

Squalenoyl nanomedicines as potential therapeutics

Nucleoside analogs such as cytarabine and gemcitabine are powerful anticancer agents, but a simple chemical modification that causes them to assemble into stable nanoparticles could make them even more valuable in the treatment of a wide variety of cancers.

23 Oct 2006

Bristol-Myers Squibb and Medivira announce collaboration to commercialize HIV treatment

Bristol-Myers Squibb and Medivir AB have announced a worldwide collaboration to develop and commercialize MIV-170, a preclinical non-nucleoside reverse transcriptase inhibitor, or NNRTI, intended for the treatment of HIV-1 infection in adults as part of an antiretroviral drug regimen.

13 Sep 2006

Researchers find way to decrease risk of atherosclerosis that accompanies long-term use of protease inhibitors

Physiologists may have found a way to decrease the risk of hardening of the arteries that accompanies the long-term use of protease inhibitors, a class of drugs that has emerged as the most effective treatment against HIV and AIDS.

5 Sep 2006